The Effect of GIP(3-30)NH2

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03770910

Acronym

GA-10

Enrollment

Registered

2018-12-10

Start date

2018-12-06

Completion date

2019-12-01

Last updated

2020-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrine - Other

Keywords

GIP, Insulin secretin, Incretin hormone

Brief summary

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Detailed description

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects. Six study hyperglycemic clamps (10 mmol/l) pr. participant.

Interventions

OTHERGIP receptor antagonist

GIP receptor antagonist

OTHERGIP receptor agonist

GIP(1-42)

OTHERSaline

Placebo (vehicle for infusions)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy * BMI 19-28 kg/m\*m * Stable body weight

Exclusion criteria

* Diabetes * Anemia * First-degree relatives with diabetes

Design outcomes

Primary

Measure	Time frame	Description
Insulin secretion	8 weeks	Insulin secretion rates (ISR) calculated from serum levels of C-peptide

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026